The latest rheumatology insights

Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Saturday 28 August
  • Sunday 29 August
  • Monday 30 August
  • Tuesday 31 August
Saturday 28th August
0945 - 1130

CH1: Plenary session 1: Opening Ceremony and Management of rheumatic diseases during the COVID-19 pandemic

Chairpersons:
Tsutomu Takeuchi and Rohini Handa

Speakers
COVID-19 in rheumatology practice in Japan
Tsutomu Takeuchi, Keio University School of Medicine

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic
Ted Mikuls, University of Nebraska

RMD and COVID19: The EULAR perspective
Robert Landewe, University of Amsterdam

1130 - 1245

CH2: Morning symposium 1

"Beyond remission” based on patients’ subjective experiences for improved RA control


Chairpersons:

Professor Masayoshi Harigai
Professor and Chairperson of Department of rheumatology/Tokyo Women’s Medical University

Speakers:

Associate Professor Yuko Kaneko
Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine

Brought to you by

CH3: Morning symposium 2

Solving the patient puzzle: A pragmatic approach to SpA management

Speakers:

Dr Mitsumasa Kishimoto
Associate Professor, Department of Nephrology and Rheumatology/Kyorin University School of Medicine

Dr Philip Robinson
Associate Professor/Brisbane Rheumatology

Brought to you by

 

 

CH4: Morning symposium 3

New treatment paradigm in RA: Focusing on a novel JAK inhibitor


Chairpersons/Speakers:

Professor Tatsuya Atsumi
Professor of Medicine in the Faculty of Medicine/Hokkaido University

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Tsutomu Takeuchi
Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine

 

Brought to you by

1245 - 1315

Break

1315 - 1445

CH1: Lunch symposium 1

Prospects for JAK inhibitors in the treatment of rheumatoid arthritis


Speakers:


Dr Kei Ikeda
Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital

Dr Akio Morinobu
Department of Rheumatology/Kyoto University Graduate School of Medicine

Brought to you by

CH 2: Lunch symposium 2

Basic and Clinical of Rheumatology


Chairpersons:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

 

Brought to you by

1445 - 1500

Break

1500 - 1640

CH1: SpA - 1: New advances in Axial
Spondyloarthritis

CH2: SLE - 1: Progress and perspectives on SLE in the APLAR region

CH3: Imaging: Imaging in rheumatic diseases - where do we stand

CH4: Treating children with rheumatic diseases in Asia Pacific: The Great Divide

Chairpersons:
Mitsumasa Kishimoto, Katy Leung, Nazrul Islam

Chairpersons:
Sandra Navarro and Yoshiya Tanaka

Chairpersons:
Chi-Chen Chang and Ved Chaturvedi

Chairpersons:
Sumaira Farman and Surjit Singh

Outcome of Juvenile spondyloarthropathy in adulthood

Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences

Patient education as vital to improving outcomes

Laniyati Hamijoyo, University of Padjadjaran

Ultrasound and its clinical use in rheumatoid arthritis

Kei Ikeda, Chiba University Hospital

Asia-Pacific Pediatric Rheumatology: Where Do We Stand

Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University

Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health

Helen Foster, Newcastle University

Treat-to-Target in SpA, how far are we going?

James Wei, Chung Shan Medical University Hospital

Progress and Perspectives on SLE in the APLAR region

Evan Vista, St. Luke's Medical Center and College of Medicine

Ultrasound in large vessel vasculitis

Kuo-Lung Lai, Taichung Veterans General Hospital

JIA: Geographic variability in treatment and long-term outcomes of JIA

Soamarat Vilaiyuk, Mahidol University

When and how to use, or not to use MRI in SpA”

Ashish Jacob Mathew, Christian Medical College

Interim report of the APLAR consensus statements on the management of SLE

Chi Chiu Mok, Tuen Mun Hospital

MRI in Rheumatoid Arthritis

Mami Tamai, Nagasaki University

Macrophage Activation Syndrome: Analysis of various Cytokines

Masaki Shimizu, Tokyo Medcial And Dental University

Novel assessment tool for bony damage in spondyloarthritis

Lai-shan Tam, The Chinese University of Hong Kong

Updates on the Asia Pacific Lupus Collaboration (APLC) cohort

Eric Morand

Ultrasound and its clinical use in spondyloarthropathy

Lee Ka Wing Gavin

Autoinflammatory disorders: Spectrum seen in Asia Pacific

Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center

Vasculitis: Childhood onset Takayasu arteritis: an update

Satish Kumar, Christian Medical College

Panel Q&A

Panel Q&A

Panel Q&A

Panel Q&A

1640 - 1740

CH1: Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki disease

CH2: Abstract session: SLE and APL syndrome 1

CH3: Abstract session: IIM, SSc, SjS

CH4: Abstract session: COVID-19 and CTD

Chairperson:
TBA

Chairperson:
Sandra Navarro

Chairperson:
Yeong-Wook Song

Chairperson:
Rohini Handa

Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still's Disease

Ji Li, Peking University International Hospital

Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome

Yu Shi, Peking Union Medical College

Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale

Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital

Rheumatic diseases on COVID-19 era

Selma Abdellaoui, Beni Messous Hospital

Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán

SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K

Masanori Kono, University of Tokyo Hospital

Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study

Jing Zhu, Sichuan Provincial People’s Hospital

Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Development of a genetic risk score for Filipino patients with systemic lupus erythematosus

Michael Tee, University of The Philippines

Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM)

Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences

Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak

Ho So, The Chinese University of Hong Kong

Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort

Devang Pandya, Dev Children's Hospital

The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus

Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine

Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan

Hiroki Furuya, Chiba University Hospital

Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India

Devang Pandya, Dev Children's Hospital

Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease - Our 40 years' experience

Tomomi Sato, Shiga University of Medical Science

Joint Q&A

Nailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

Tomohiro Sugimoto, Hiroshima University Hospital

Reactive arthritis after COVID-19 infection

Keisuke Ono, Kyorin University School of Medicine

Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease

Aya Nishiwaki, The University of Tokyo

Is Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies?

Bugra Han Egeli

A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19

Vincent Anthony Tang, University Of The Philippines - Philippine General Hospital

Joint Q&A

Joint Q&A

Assessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka

Sunith Atukorale, Ministry of Health

Joint Q&A

1740 - 1840

CH1: Evening symposium 1

Management of RA in 2020: is remission achievable and where do JAKs fit?


Speakers:

Professor Gerd-Rüdiger Burmester
Medicine Director of the department of Rheumatology

Associate Professor Peter Nash
Department of Medicine/University of Queensland, Brisbane, AUSTRALIA

 

Brought to you by

CH2: Evening symposium 2

Treat-to-target in SLE: addressing short- and long-term treatment goals


Chariperson:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Ian Bruce
National Institute of Health Research (NIHR) Senior Investigator and Professor of Rheumatology/University of Manchester

Professor Nancy Agmon-Levin
Consultant/Tel Aviv and Chaim Sheba Medical Center

 

Brought to you by

CH3: Evening symposium 3

ILD in Focus: Time to prioritize the lung in CTDs


Chairperson:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Professor Yannick Allanore
Professor of Rheumatology/University of Paris

Professor Marco Matucci-Cerinic
Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence

 

Brought to you by

CH4: Evening symposium 4

Perspectives around the accumulated evidence for IL-6 in autoimmune disease


Chairpersons/Speakers:

Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Dr Shinsuke Yasuda
Tokyo Medical and Dental University, Department of Rheumatology, Japan

 

Brought to you by

Sunday 29th August
0945 - 1130

CH1: Plenary session 1: Opening Ceremony and Management of rheumatic diseases during the COVID-19 pandemic

Chairpersons:
Tsutomu Takeuchi and Rohini Handa

Speakers
COVID-19 in rheumatology practice in Japan
Tsutomu Takeuchi, Keio University School of Medicine

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic
Ted Mikuls, University of Nebraska

RMD and COVID19: The EULAR perspective
Robert Landewe, University of Amsterdam

1130 - 1245

CH2: Morning symposium 1

"Beyond remission” based on patients’ subjective experiences for improved RA control


Chairpersons:

Professor Masayoshi Harigai
Professor and Chairperson of Department of rheumatology/Tokyo Women’s Medical University

Speakers:

Associate Professor Yuko Kaneko
Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine

Brought to you by

CH3: Morning symposium 2

Solving the patient puzzle: A pragmatic approach to SpA management

Speakers:

Dr Mitsumasa Kishimoto
Associate Professor, Department of Nephrology and Rheumatology/Kyorin University School of Medicine

Dr Philip Robinson
Associate Professor/Brisbane Rheumatology

Brought to you by

 

 

CH4: Morning symposium 3

New treatment paradigm in RA: Focusing on a novel JAK inhibitor


Chairpersons/Speakers:

Professor Tatsuya Atsumi
Professor of Medicine in the Faculty of Medicine/Hokkaido University

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Tsutomu Takeuchi
Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine

 

Brought to you by

1245 - 1315

Break

1315 - 1445

CH1: Lunch symposium 1

Prospects for JAK inhibitors in the treatment of rheumatoid arthritis


Speakers:


Dr Kei Ikeda
Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital

Dr Akio Morinobu
Department of Rheumatology/Kyoto University Graduate School of Medicine

Brought to you by

CH 2: Lunch symposium 2

Basic and Clinical of Rheumatology


Chairpersons:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

 

Brought to you by

1445 - 1500

Break

1500 - 1640

CH1: SpA - 1: New advances in Axial
Spondyloarthritis

CH2: SLE - 1: Progress and perspectives on SLE in the APLAR region

CH3: Imaging: Imaging in rheumatic diseases - where do we stand

CH4: Treating children with rheumatic diseases in Asia Pacific: The Great Divide

Chairpersons:
Mitsumasa Kishimoto, Katy Leung, Nazrul Islam

Chairpersons:
Sandra Navarro and Yoshiya Tanaka

Chairpersons:
Chi-Chen Chang and Ved Chaturvedi

Chairpersons:
Sumaira Farman and Surjit Singh

Outcome of Juvenile spondyloarthropathy in adulthood

Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences

Patient education as vital to improving outcomes

Laniyati Hamijoyo, University of Padjadjaran

Ultrasound and its clinical use in rheumatoid arthritis

Kei Ikeda, Chiba University Hospital

Asia-Pacific Pediatric Rheumatology: Where Do We Stand

Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University

Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health

Helen Foster, Newcastle University

Treat-to-Target in SpA, how far are we going?

James Wei, Chung Shan Medical University Hospital

Progress and Perspectives on SLE in the APLAR region

Evan Vista, St. Luke's Medical Center and College of Medicine

Ultrasound in large vessel vasculitis

Kuo-Lung Lai, Taichung Veterans General Hospital

JIA: Geographic variability in treatment and long-term outcomes of JIA

Soamarat Vilaiyuk, Mahidol University

When and how to use, or not to use MRI in SpA”

Ashish Jacob Mathew, Christian Medical College

Interim report of the APLAR consensus statements on the management of SLE

Chi Chiu Mok, Tuen Mun Hospital

MRI in Rheumatoid Arthritis

Mami Tamai, Nagasaki University

Macrophage Activation Syndrome: Analysis of various Cytokines

Masaki Shimizu, Tokyo Medcial And Dental University

Novel assessment tool for bony damage in spondyloarthritis

Lai-shan Tam, The Chinese University of Hong Kong

Updates on the Asia Pacific Lupus Collaboration (APLC) cohort

Eric Morand

Ultrasound and its clinical use in spondyloarthropathy

Lee Ka Wing Gavin

Autoinflammatory disorders: Spectrum seen in Asia Pacific

Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center

Vasculitis: Childhood onset Takayasu arteritis: an update

Satish Kumar, Christian Medical College

Panel Q&A

Panel Q&A

Panel Q&A

Panel Q&A

1640 - 1740

CH1: Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki disease

CH2: Abstract session: SLE and APL syndrome 1

CH3: Abstract session: IIM, SSc, SjS

CH4: Abstract session: COVID-19 and CTD

Chairperson:
TBA

Chairperson:
Sandra Navarro

Chairperson:
Yeong-Wook Song

Chairperson:
Rohini Handa

Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still's Disease

Ji Li, Peking University International Hospital

Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome

Yu Shi, Peking Union Medical College

Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale

Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital

Rheumatic diseases on COVID-19 era

Selma Abdellaoui, Beni Messous Hospital

Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán

SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K

Masanori Kono, University of Tokyo Hospital

Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study

Jing Zhu, Sichuan Provincial People’s Hospital

Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Development of a genetic risk score for Filipino patients with systemic lupus erythematosus

Michael Tee, University of The Philippines

Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM)

Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences

Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak

Ho So, The Chinese University of Hong Kong

Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort

Devang Pandya, Dev Children's Hospital

The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus

Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine

Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan

Hiroki Furuya, Chiba University Hospital

Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India

Devang Pandya, Dev Children's Hospital

Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease - Our 40 years' experience

Tomomi Sato, Shiga University of Medical Science

Joint Q&A

Nailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

Tomohiro Sugimoto, Hiroshima University Hospital

Reactive arthritis after COVID-19 infection

Keisuke Ono, Kyorin University School of Medicine

Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease

Aya Nishiwaki, The University of Tokyo

Is Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies?

Bugra Han Egeli

A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19

Vincent Anthony Tang, University Of The Philippines - Philippine General Hospital

Joint Q&A

Joint Q&A

Assessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka

Sunith Atukorale, Ministry of Health

Joint Q&A

1740 - 1840

CH1: Evening symposium 1

Management of RA in 2020: is remission achievable and where do JAKs fit?


Speakers:

Professor Gerd-Rüdiger Burmester
Medicine Director of the department of Rheumatology

Associate Professor Peter Nash
Department of Medicine/University of Queensland, Brisbane, AUSTRALIA

 

Brought to you by

CH2: Evening symposium 2

Treat-to-target in SLE: addressing short- and long-term treatment goals


Chariperson:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Ian Bruce
National Institute of Health Research (NIHR) Senior Investigator and Professor of Rheumatology/University of Manchester

Professor Nancy Agmon-Levin
Consultant/Tel Aviv and Chaim Sheba Medical Center

 

Brought to you by

CH3: Evening symposium 3

ILD in Focus: Time to prioritize the lung in CTDs


Chairperson:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Professor Yannick Allanore
Professor of Rheumatology/University of Paris

Professor Marco Matucci-Cerinic
Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence

 

Brought to you by

CH4: Evening symposium 4

Perspectives around the accumulated evidence for IL-6 in autoimmune disease


Chairpersons/Speakers:

Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Dr Shinsuke Yasuda
Tokyo Medical and Dental University, Department of Rheumatology, Japan

 

Brought to you by

Monday 30th August
0945 - 1130

CH1: Plenary session 1: Opening Ceremony and Management of rheumatic diseases during the COVID-19 pandemic

Chairpersons:
Tsutomu Takeuchi and Rohini Handa

Speakers
COVID-19 in rheumatology practice in Japan
Tsutomu Takeuchi, Keio University School of Medicine

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic
Ted Mikuls, University of Nebraska

RMD and COVID19: The EULAR perspective
Robert Landewe, University of Amsterdam

1130 - 1245

CH2: Morning symposium 1

"Beyond remission” based on patients’ subjective experiences for improved RA control


Chairpersons:

Professor Masayoshi Harigai
Professor and Chairperson of Department of rheumatology/Tokyo Women’s Medical University

Speakers:

Associate Professor Yuko Kaneko
Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine

Brought to you by

CH3: Morning symposium 2

Solving the patient puzzle: A pragmatic approach to SpA management

Speakers:

Dr Mitsumasa Kishimoto
Associate Professor, Department of Nephrology and Rheumatology/Kyorin University School of Medicine

Dr Philip Robinson
Associate Professor/Brisbane Rheumatology

Brought to you by

 

 

CH4: Morning symposium 3

New treatment paradigm in RA: Focusing on a novel JAK inhibitor


Chairpersons/Speakers:

Professor Tatsuya Atsumi
Professor of Medicine in the Faculty of Medicine/Hokkaido University

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Tsutomu Takeuchi
Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine

 

Brought to you by

1245 - 1315

Break

1315 - 1445

CH1: Lunch symposium 1

Prospects for JAK inhibitors in the treatment of rheumatoid arthritis


Speakers:


Dr Kei Ikeda
Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital

Dr Akio Morinobu
Department of Rheumatology/Kyoto University Graduate School of Medicine

Brought to you by

CH 2: Lunch symposium 2

Basic and Clinical of Rheumatology


Chairpersons:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

 

Brought to you by

1445 - 1500

Break

1500 - 1640

CH1: SpA - 1: New advances in Axial
Spondyloarthritis

CH2: SLE - 1: Progress and perspectives on SLE in the APLAR region

CH3: Imaging: Imaging in rheumatic diseases - where do we stand

CH4: Treating children with rheumatic diseases in Asia Pacific: The Great Divide

Chairpersons:
Mitsumasa Kishimoto, Katy Leung, Nazrul Islam

Chairpersons:
Sandra Navarro and Yoshiya Tanaka

Chairpersons:
Chi-Chen Chang and Ved Chaturvedi

Chairpersons:
Sumaira Farman and Surjit Singh

Outcome of Juvenile spondyloarthropathy in adulthood

Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences

Patient education as vital to improving outcomes

Laniyati Hamijoyo, University of Padjadjaran

Ultrasound and its clinical use in rheumatoid arthritis

Kei Ikeda, Chiba University Hospital

Asia-Pacific Pediatric Rheumatology: Where Do We Stand

Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University

Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health

Helen Foster, Newcastle University

Treat-to-Target in SpA, how far are we going?

James Wei, Chung Shan Medical University Hospital

Progress and Perspectives on SLE in the APLAR region

Evan Vista, St. Luke's Medical Center and College of Medicine

Ultrasound in large vessel vasculitis

Kuo-Lung Lai, Taichung Veterans General Hospital

JIA: Geographic variability in treatment and long-term outcomes of JIA

Soamarat Vilaiyuk, Mahidol University

When and how to use, or not to use MRI in SpA”

Ashish Jacob Mathew, Christian Medical College

Interim report of the APLAR consensus statements on the management of SLE

Chi Chiu Mok, Tuen Mun Hospital

MRI in Rheumatoid Arthritis

Mami Tamai, Nagasaki University

Macrophage Activation Syndrome: Analysis of various Cytokines

Masaki Shimizu, Tokyo Medcial And Dental University

Novel assessment tool for bony damage in spondyloarthritis

Lai-shan Tam, The Chinese University of Hong Kong

Updates on the Asia Pacific Lupus Collaboration (APLC) cohort

Eric Morand

Ultrasound and its clinical use in spondyloarthropathy

Lee Ka Wing Gavin

Autoinflammatory disorders: Spectrum seen in Asia Pacific

Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center

Vasculitis: Childhood onset Takayasu arteritis: an update

Satish Kumar, Christian Medical College

Panel Q&A

Panel Q&A

Panel Q&A

Panel Q&A

1640 - 1740

CH1: Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki disease

CH2: Abstract session: SLE and APL syndrome 1

CH3: Abstract session: IIM, SSc, SjS

CH4: Abstract session: COVID-19 and CTD

Chairperson:
TBA

Chairperson:
Sandra Navarro

Chairperson:
Yeong-Wook Song

Chairperson:
Rohini Handa

Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still's Disease

Ji Li, Peking University International Hospital

Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome

Yu Shi, Peking Union Medical College

Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale

Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital

Rheumatic diseases on COVID-19 era

Selma Abdellaoui, Beni Messous Hospital

Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán

SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K

Masanori Kono, University of Tokyo Hospital

Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study

Jing Zhu, Sichuan Provincial People’s Hospital

Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Development of a genetic risk score for Filipino patients with systemic lupus erythematosus

Michael Tee, University of The Philippines

Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM)

Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences

Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak

Ho So, The Chinese University of Hong Kong

Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort

Devang Pandya, Dev Children's Hospital

The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus

Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine

Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan

Hiroki Furuya, Chiba University Hospital

Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India

Devang Pandya, Dev Children's Hospital

Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease - Our 40 years' experience

Tomomi Sato, Shiga University of Medical Science

Joint Q&A

Nailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

Tomohiro Sugimoto, Hiroshima University Hospital

Reactive arthritis after COVID-19 infection

Keisuke Ono, Kyorin University School of Medicine

Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease

Aya Nishiwaki, The University of Tokyo

Is Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies?

Bugra Han Egeli

A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19

Vincent Anthony Tang, University Of The Philippines - Philippine General Hospital

Joint Q&A

Joint Q&A

Assessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka

Sunith Atukorale, Ministry of Health

Joint Q&A

1740 - 1840

CH1: Evening symposium 1

Management of RA in 2020: is remission achievable and where do JAKs fit?


Speakers:

Professor Gerd-Rüdiger Burmester
Medicine Director of the department of Rheumatology

Associate Professor Peter Nash
Department of Medicine/University of Queensland, Brisbane, AUSTRALIA

 

Brought to you by

CH2: Evening symposium 2

Treat-to-target in SLE: addressing short- and long-term treatment goals


Chariperson:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Ian Bruce
National Institute of Health Research (NIHR) Senior Investigator and Professor of Rheumatology/University of Manchester

Professor Nancy Agmon-Levin
Consultant/Tel Aviv and Chaim Sheba Medical Center

 

Brought to you by

CH3: Evening symposium 3

ILD in Focus: Time to prioritize the lung in CTDs


Chairperson:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Professor Yannick Allanore
Professor of Rheumatology/University of Paris

Professor Marco Matucci-Cerinic
Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence

 

Brought to you by

CH4: Evening symposium 4

Perspectives around the accumulated evidence for IL-6 in autoimmune disease


Chairpersons/Speakers:

Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Dr Shinsuke Yasuda
Tokyo Medical and Dental University, Department of Rheumatology, Japan

 

Brought to you by

Tuesday 31st August
0945 - 1130

CH1: Plenary session 1: Opening Ceremony and Management of rheumatic diseases during the COVID-19 pandemic

Chairpersons:
Tsutomu Takeuchi and Rohini Handa

Speakers
COVID-19 in rheumatology practice in Japan
Tsutomu Takeuchi, Keio University School of Medicine

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic
Ted Mikuls, University of Nebraska

RMD and COVID19: The EULAR perspective
Robert Landewe, University of Amsterdam

1130 - 1245

CH2: Morning symposium 1

"Beyond remission” based on patients’ subjective experiences for improved RA control


Chairpersons:

Professor Masayoshi Harigai
Professor and Chairperson of Department of rheumatology/Tokyo Women’s Medical University

Speakers:

Associate Professor Yuko Kaneko
Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine

Brought to you by

CH3: Morning symposium 2

Solving the patient puzzle: A pragmatic approach to SpA management

Speakers:

Dr Mitsumasa Kishimoto
Associate Professor, Department of Nephrology and Rheumatology/Kyorin University School of Medicine

Dr Philip Robinson
Associate Professor/Brisbane Rheumatology

Brought to you by

 

 

CH4: Morning symposium 3

New treatment paradigm in RA: Focusing on a novel JAK inhibitor


Chairpersons/Speakers:

Professor Tatsuya Atsumi
Professor of Medicine in the Faculty of Medicine/Hokkaido University

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Tsutomu Takeuchi
Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine

 

Brought to you by

1245 - 1315

Break

1315 - 1445

CH1: Lunch symposium 1

Prospects for JAK inhibitors in the treatment of rheumatoid arthritis


Speakers:


Dr Kei Ikeda
Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital

Dr Akio Morinobu
Department of Rheumatology/Kyoto University Graduate School of Medicine

Brought to you by

CH 2: Lunch symposium 2

Basic and Clinical of Rheumatology


Chairpersons:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

 

Brought to you by

1445 - 1500

Break

1500 - 1640

CH1: SpA - 1: New advances in Axial
Spondyloarthritis

CH2: SLE - 1: Progress and perspectives on SLE in the APLAR region

CH3: Imaging: Imaging in rheumatic diseases - where do we stand

CH4: Treating children with rheumatic diseases in Asia Pacific: The Great Divide

Chairpersons:
Mitsumasa Kishimoto, Katy Leung, Nazrul Islam

Chairpersons:
Sandra Navarro and Yoshiya Tanaka

Chairpersons:
Chi-Chen Chang and Ved Chaturvedi

Chairpersons:
Sumaira Farman and Surjit Singh

Outcome of Juvenile spondyloarthropathy in adulthood

Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences

Patient education as vital to improving outcomes

Laniyati Hamijoyo, University of Padjadjaran

Ultrasound and its clinical use in rheumatoid arthritis

Kei Ikeda, Chiba University Hospital

Asia-Pacific Pediatric Rheumatology: Where Do We Stand

Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University

Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health

Helen Foster, Newcastle University

Treat-to-Target in SpA, how far are we going?

James Wei, Chung Shan Medical University Hospital

Progress and Perspectives on SLE in the APLAR region

Evan Vista, St. Luke's Medical Center and College of Medicine

Ultrasound in large vessel vasculitis

Kuo-Lung Lai, Taichung Veterans General Hospital

JIA: Geographic variability in treatment and long-term outcomes of JIA

Soamarat Vilaiyuk, Mahidol University

When and how to use, or not to use MRI in SpA”

Ashish Jacob Mathew, Christian Medical College

Interim report of the APLAR consensus statements on the management of SLE

Chi Chiu Mok, Tuen Mun Hospital

MRI in Rheumatoid Arthritis

Mami Tamai, Nagasaki University

Macrophage Activation Syndrome: Analysis of various Cytokines

Masaki Shimizu, Tokyo Medcial And Dental University

Novel assessment tool for bony damage in spondyloarthritis

Lai-shan Tam, The Chinese University of Hong Kong

Updates on the Asia Pacific Lupus Collaboration (APLC) cohort

Eric Morand

Ultrasound and its clinical use in spondyloarthropathy

Lee Ka Wing Gavin

Autoinflammatory disorders: Spectrum seen in Asia Pacific

Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center

Vasculitis: Childhood onset Takayasu arteritis: an update

Satish Kumar, Christian Medical College

Panel Q&A

Panel Q&A

Panel Q&A

Panel Q&A

1640 - 1740

CH1: Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki disease

CH2: Abstract session: SLE and APL syndrome 1

CH3: Abstract session: IIM, SSc, SjS

CH4: Abstract session: COVID-19 and CTD

Chairperson:
TBA

Chairperson:
Sandra Navarro

Chairperson:
Yeong-Wook Song

Chairperson:
Rohini Handa

Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still's Disease

Ji Li, Peking University International Hospital

Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome

Yu Shi, Peking Union Medical College

Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale

Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital

Rheumatic diseases on COVID-19 era

Selma Abdellaoui, Beni Messous Hospital

Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán

SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K

Masanori Kono, University of Tokyo Hospital

Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study

Jing Zhu, Sichuan Provincial People’s Hospital

Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy

Shengxiao Zhang, The Second Hospital of Shanxi Medical University

Development of a genetic risk score for Filipino patients with systemic lupus erythematosus

Michael Tee, University of The Philippines

Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM)

Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences

Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak

Ho So, The Chinese University of Hong Kong

Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort

Devang Pandya, Dev Children's Hospital

The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus

Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine

Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan

Hiroki Furuya, Chiba University Hospital

Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India

Devang Pandya, Dev Children's Hospital

Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease - Our 40 years' experience

Tomomi Sato, Shiga University of Medical Science

Joint Q&A

Nailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

Tomohiro Sugimoto, Hiroshima University Hospital

Reactive arthritis after COVID-19 infection

Keisuke Ono, Kyorin University School of Medicine

Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease

Aya Nishiwaki, The University of Tokyo

Is Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies?

Bugra Han Egeli

A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19

Vincent Anthony Tang, University Of The Philippines - Philippine General Hospital

Joint Q&A

Joint Q&A

Assessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka

Sunith Atukorale, Ministry of Health

Joint Q&A

1740 - 1840

CH1: Evening symposium 1

Management of RA in 2020: is remission achievable and where do JAKs fit?


Speakers:

Professor Gerd-Rüdiger Burmester
Medicine Director of the department of Rheumatology

Associate Professor Peter Nash
Department of Medicine/University of Queensland, Brisbane, AUSTRALIA

 

Brought to you by

CH2: Evening symposium 2

Treat-to-target in SLE: addressing short- and long-term treatment goals


Chariperson:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Speakers:

Professor Yoshiya Tanaka
Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health

Professor Ian Bruce
National Institute of Health Research (NIHR) Senior Investigator and Professor of Rheumatology/University of Manchester

Professor Nancy Agmon-Levin
Consultant/Tel Aviv and Chaim Sheba Medical Center

 

Brought to you by

CH3: Evening symposium 3

ILD in Focus: Time to prioritize the lung in CTDs


Chairperson:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Speakers:

Professor Masataka Kuwana
Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School

Professor Yannick Allanore
Professor of Rheumatology/University of Paris

Professor Marco Matucci-Cerinic
Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence

 

Brought to you by

CH4: Evening symposium 4

Perspectives around the accumulated evidence for IL-6 in autoimmune disease


Chairpersons/Speakers:

Dr Kunihiro Yamaoka
Division of Rheumatology, Kitasato University Hospital, Japan

Dr Shinsuke Yasuda
Tokyo Medical and Dental University, Department of Rheumatology, Japan

 

Brought to you by

Janssen logo

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Asahi Kasei Logo

Asahi Kasei Pharma Corporation

Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology, the immune system, and the central nervous system.

Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, each of which has a competitive position in its respective market.

Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.

Kevzara® is a registered trademark of Sanofi Biotechnology.

The product information is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin.

Product availability, names, indications, and presentations may vary from country to country.

Janssen_300x300

Janssen, a division of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Lilly logo

Eli Lilly Japan K.K.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Abbvie logo

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Bristol Myers Squibb logo

Bristol Myers Squibb K.K.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Gilead logo

Gilead Sciences K.K.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.

Novartis logo

Novartis Pharma K.K.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We consistently rank among the world’s top companies investing in research and development.

Pfizer logo

Pfizer. Japan Inc

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Astellas logo

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

Boehringer Ingelheim logo

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of

19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: www.annualreport.boehringer-ingelheim.com.

Chugai logo

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Daiichi-Sankyo logo

Daiichi Sankyo Co., Ltd.

GSK Logo

Glaxosmithkline

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

UCB logo

UCB Biopharma SRL

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines. Our ambition is to transform the lives of people living with severe diseases, with a focus in immunology and neurology.

CSF Logo

Cesas Medical

The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

AWR logo

Association of Women in Rheumatology

AWIR is a global organization with more than 11,000 touchpoints and 8 global chapters/partners worldwide. AWIR’s mission is to promote the science and practice of Rheumatology, foster the advancement and education of women in Rheumatology, and advocate access to the highest quality health care, and the management of patients with Rheumatic diseases.

LG Chem logo

LG Chem

LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

Contact
APLAR21-Placeholder (300x300)

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Contact